Stockwinners Market Radar for February 12, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EST Cathie Wood's ARK Investment bought 455.2K shares of Archer Aviation today

19:58 EST Intuitive Machines, SpaceX complete successful IM-1 test campaign - Intuitive Machines and SpaceX have analyzed the data from the lunar lander fueling tests for the IM-1 mission and determined the testing campaign is complete. Liftoff of the IM-1 mission is targeted for a multi-day launch window that opens at 12:57 a.m. Eastern Standard Time on February 14, 2024, from Launch Complex 39A at NASA's Kennedy Space Center in Florida. The Intuitive Machines IM-1 mission is the Company's first attempted lunar landing as part of NASA's Commercial Lunar Payload Services initiative, a key part of NASA's Artemis lunar exploration efforts.

18:39 EST Harmony Biosciences' treatment of PWS receives FDA orphan designation - According to a post on the FDA's website, Harmony Biosciences' treatment of Prader-Willi syndrome received orphan designation. Reference Link

18:29 EST Flame Acquisition Corp. reports holder approval of Sable business combination - Flame Acquisition Corp., a special purpose acquisition company, announced the results for the proposals considered and voted upon by its stockholders at its special meeting on February 12, 2024. Flame reported that all of the proposals submitted to its stockholders in connection with the previously announced business combination among Flame, Sable Offshore Holdings, LLC, and Sable Offshore Corp., were approved by the requisite number of shares of Flame common stock voted at the special meeting. A Current Report on Form 8-K disclosing the full voting results will be filed with the Securities and Exchange Commission on February 12, 2024. The deadline for electing redemptions of Flame common stock has passed, and Flame will have approximately $62.2M in its trust account prior to the business combination. The closing of the business combination is expected to occur on or about February 14, 2024, subject to the satisfaction or waiver of all closing conditions. Following the closing of the business combination, the combined company will be renamed "Sable Offshore Corp." and its common stock and public warrants are expected to begin trading on the New York Stock Exchange under the ticker symbols "SOC" and "SOC.WS," respectively, commencing on February 15, 2024.

18:02 EST Otter Tail raises quarterly dividend to 7% 46.75c per share - The corporation's board of directors increased the quarterly common stock dividend to 46.75c per share, an indicated annual dividend rate of $1.87 per share in 2024, a 7% increase from $1.75 per share in 2023.

17:52 EST Vestis CEO buys $287K in common stock - In a regulatory filing, Vestis disclosed that its CEO Kim Scott bought 15K shares of common stock on February 9th in a total transaction size of $287K. Shares of Vestis are up 4% afterhours at $20.18.

17:49 EST Carl Icahn reports 9.91% stake in JetBlue, held talks over board seats

17:41 EST Tractor Supply CEO sells $4.78M in common stock - In a regulatory filing, Tractor Supply disclosed that its CEO Harry Lawton sold 20.5K shares of common stock on February 8th in a total transaction size of $4.78M.

17:35 EST Star Bulk Carriers says Eagle Bulk Shipping merger expected to close in 1H24

17:27 EST Group 1 Automotive announces expansion of U.S. portfolio - Group 1 Automotive announced the expansion of its U.S. portfolio in the greater Baltimore/Washington DC market, the sixth largest metropolitan area in the United States. The acquisition includes Toyota, Honda, Hyundai, and Kia new vehicle dealerships; one Toyota Certified pre-owned center; and three collision centers. The group includes the two highest volume Honda dealerships in the state of Maryland. The dealerships are expected to generate over $500M in annual revenues.

16:42 EST Oragenics, CEO Kimberly Murphy enter into separation agreement - Oragenics "announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company's Chief Executive Officer, entered into a mutually agreeable Separation Agreement, pursuant to which Ms. Murphy's employment with the Company terminated effective February 12, 2024. Ms. Murphy will, however, continue to serve the Company as a member of the Company's board of directors. The Separation Agreement provides Ms. Murphy with the benefits under her employment agreement with the Company for a separation without cause. Ms. Murphy's resignation as an officer was not due to any disagreement with the Company on any matter related to its operations, policies or practices."

16:33 EST Goodyear Tire reports Q4 tire unit volume of 45.4M units, down 3.8% y/y - Global replacement volume was lower by 6.7%, reflecting a strong fourth quarter 2022 comparable for Americas and continued weak trends in EMEA. Global OE volume increased 6.0%, driven by share gains in Asia Pacific.

16:31 EST Victory Capital reports January AUM $165.5B - Victory Capital Holdings reported assets under management of $165.5B as of January 31, 2024, vs. $166.6B last month and average assets under management for January of $165.6B.

16:27 EST Goodyear Tire sees Q1 global unit volumes down about 2% - Driven by replacement. Sees Q1 raw material costs down about $245M vs. prior year.

16:24 EST Liberty TripAdvisor authorizes talks to potentially acquire TripAdvisor - Liberty TripAdvisor Holdings (LTRPA), which owns 29.25M shares of TripAdvisor (TRIP) or 211% of the outstanding shares, disclosed that its board of directors authorized the company to engage in discussions with respect to a potential transaction, pursuant to which all of the outstanding stock of the Liberty TripAdvisor and all of TripAdvisor's outstanding common stock would be acquired concurrently for cash. TripAdvisor's board has formed a special committee comprised of independent and disinterested directors of the board. The special committee has authorized the company to, among other things, engage in discussions with respect to a potential transaction. Shares of TripAdvisor are up 11% to $24.93 in after-hours trading following the disclosure.

16:22 EST Invesco sees January AUM down 0,1% to $1,583B - Invesco reported preliminary month-end assets under management, or AUM, of $1,583B, a decrease of 0.1% versus previous month-end. The firm delivered net long-term inflows of $1.7B in the month. Non-management fee earning net inflows were $5.8B and money market net outflows were $1.3B. AUM was negatively impacted by unfavorable market returns which decreased AUM by $3B. FX decreased AUM by $4.4B. Preliminary average total AUM for the quarter through January 31 were $1,579B, and preliminary average active AUM for the quarter through January 31 were $973.0B.

16:19 EST Sterling Infrastructure announces retirement plan of CFO Ronald Ballschmiede - Sterling Infrastructure announced that Ronald Ballschmiede, Sterling's CFO has informed the Company of his plan to retire in 2024. "Ron has been a tremendous partner as we worked to build Sterling into the company it is today," stated Joe Cutillo, Sterling's CEO. "We have a succession plan in place. Ron will stay on as CFO until his successor is named and will continue thereafter to ensure a smooth transition."

16:19 EST Principal Financial announces new repurchase authorization for $1.5B - The Board of Directors approved a new authorization for the repurchase of $1.5 billion of the company's outstanding common stock. As of December 31, 2023, approximately $0.3 billion remained under the company's prior authorization.

16:14 EST AllianceBernstein reports preliminary AUM $726B as of January 31 - AllianceBernstein announced that preliminary assets under management increased to $726B during January 2024 from $725B at the end of December. January AUM reflected market gains, partially offset by net outflows. By channel, net inflows to Retail were offset by net outflows from Institutions and Private Wealth.

16:10 EST Anywhere Real Estate names Rudy Wolfs as CTO, COO McSherry steps down - Anywhere Real Estate announced the appointment of technology leader Rudy Wolfs as Chief Technology Officer, effective February 22. The company also announced the decision by Melissa McSherry to step down as COO, effective February 26, and serve as a strategic advisor to Anywhere until April 1. Wolfs most recently led a digital start-up company.

16:09 EST Virtus Investment reports preliminary AUM of $171.1B as of January 31 - Virtus Investment Partners reported preliminary assets under management of $171.1B as of January 31, 2024. In addition, the company provided services to $2.6B of other fee-earning assets, which are not included in assets under management.

16:08 EST TripAdvisor forms special committee of independent directors - Tripadvisor announced the formation of a Special Committee comprised of independent directors of the Board of Directors of Tripadvisor. The mandate of the Special Committee is to evaluate any proposals that may be brought forward for a potential transaction, and any alternatives thereto, with regard to Tripadvisor, including those that may arise in the future as a result of the recent Liberty TripAdvisor Holdings disclosure of its intent to evaluate potential alternatives involving LTRP and Tripadvisor. The Special Committee has retained Centerview Partners LLC as its financial advisor in connection with its evaluation.

16:06 EST Avis Budget reports Q4 EPS $7.10, consensus $4.15 - Reports Q4 revenue $2.76B, consensus $2.81B. "We concluded the year with record revenue and the second-best Adjusted EBITDA in our Company's history. We achieved this through continued demand improvement, seasonally adjusted price well above historical levels, and reducing the costs in our control," said Joe Ferraro, Avis Budget Group Chief Executive Officer. "We finished the year with the highest volume of rentals in our fourth quarter history, and our employees seamlessly provided exceptional service. I want to thank them for their efforts, and we look forward to another successful year in 2024."

16:05 EST Santander Chile unit in deal to buy Mundo Credito's auto loans for $79M - Banco Santander Chile's announced that its subsidiary Santander Consumer Finance will acquire Mundo Credito in an operation for up to $ 79M. The operation is subject to the approval of the National Economic Prosecutor's Office, the due diligence process and other usual conditions precedent...The operation would reach between $50,000 million and $70,000 million, being subject to the approval of the National Economic Prosecutor's Office, the due diligence process and other usual conditions precedent. Cristian Amar, CEO of Santander Consumer, pointed out that "we accompany people in their decisions that allow them to achieve greater well-being and better living conditions. In that sense, for families, purchasing a vehicle is one of the most important purchasing decisions. At Santander Consumer we are very happy with this step, because with this operation we strengthen our offer in this market." Indeed, thanks to this operation, Santander Consumer consolidates its position as one of the main players in this industry, thus allowing it to reach new customers.

13:29 EST GM's Cruise names Steve Kenner as chief safety officer - Cruise LLC announced it has hired Steve Kenner as its Chief Safety Officer. Kenner will oversee Cruise's safety management systems and operations, working in direct partnership with the Cruise Board of Directors. In his new role, Kenner will report to Cruise President and Chief Administrative Officer Craig Glidden. "As we look forward to Cruise's next chapter, we know we must continually improve our overall safety performance and work to build trust with regulators, other government officials and our communities," said Glidden. "Steve Kenner brings the perfect blend of experience in AV and automotive safety excellence to help deliver on these important priorities." "Safety governance is a critical gating factor as we return to our mission and get Cruise cars back on the road safely," said Mo Elshenawy, President and Chief Technology Officer at Cruise. "We know that safety is a mindset every engineer and employee throughout Cruise embraces, and that greater accountability will be developed through Steve's expert leadership." Reference Link

12:21 EST Bitcoin price tops $50,000 for first time since December 2021 - Publicly traded companies in the cryptocurrency space include Bit Digital (BTBT), Coinbase (COIN), Core Scientific (CORZ), Greenidge Generation (GREE), Marathon Digital (MARA), MicroStrategy (MSTR), Riot Platforms (RIOT), Stronghold Digital Mining (SDIG) and TeraWulf (WULF).

12:00 EST Alto Neuroscience falls -6.3% - Alto Neuroscience is down -6.3%, or -$1.04 to $15.51.

12:00 EST Big Lots falls -31.5% - Big Lots is down -31.5%, or -$1.69 to $3.67.

12:00 EST Skillz rises 12.8% - Skillz is up 12.8%, or 83c to $7.30.

11:32 EST Nasdaq, Ministry of Economy of Ukraine sign MOU to facilitate entrepreneurism - Nasdaq and the Ministry of Economy of Ukraine announced the signing of a Memorandum of Understanding to support Ukraine's efforts to strengthen its economy and capital markets. As a part of the agreement, Nasdaq and the Ministry of Economy of Ukraine will identify areas of collaboration that can advance the restoration and recovery of Ukraine's economy throughout the country's reconstruction process. This will include identifying ways in which both parties can provide technical assistance for the forthcoming international finance center in Ukraine, promote entrepreneurism among Ukrainian citizens, and facilitate capital formation for Ukrainian companies. Nasdaq also intends to waive listing fees for Ukrainian companies listing on Nasdaq's U.S. and European markets. The fee waiver is subject to regulatory approvals.

11:02 EST Huron enters agreement to acquire GG+A, terms not disclosed - Huron has entered into an agreement to acquire GG+A, a philanthropic management consulting firm that helps education institutions and healthcare, arts and other nonprofit organizations build and accelerate the philanthropic programs that support their mission. Founded in 1961, GG+A collaborates with clients across the globe to understand their unique fundraising landscape and develop sustainable, high-performing institutional programs that help accelerate their growth strategies, strengthen constituent experiences that build stronger donor and alumni relationships, and improve productivity. Approximately 100 members of the GG+A team will join Huron. GG+A will be included in Huron's Education operating segment. Terms of the acquisition, which is expected to close in March 2024, were not disclosed.

10:46 EST Phoenix Biotech Acquisition Corp trading halted, volatility trading pause

10:02 EST Assure Holdings enters plan of merger with Danam Health - Assure Holdings has entered into a definitive Agreement and Plan of Merger with Danam Health under which Danam will merge with a newly-formed, wholly-owned subsidiary of Assure in a stock-for-stock transaction in which Danam will survive as a wholly-owned subsidiary of Assure. Assure will change its name to "Danam Health Holdings Corp." and the combined company is intended to continue as a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on pharmaceutical and healthcare services that will advance Danam's micro health ecosystem, and is anticipated to include a portfolio of companies with pharmacy, wholesale operations and a technology division with a novel platform for hub and clinical services. Danam is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, Danam intends to shift the dynamic of care to revolve around the patient for a wide range of therapeutic conditions. Danam offers a full spectrum of integrated solutions by leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from "specialty-lite" to general maintenance conditions. The Merger is structured as a stock for stock exchange whereby all of the outstanding equity securities of Danam are to be exchanged for shares of Assure common stock. Upon completion of the proposed Merger, on a pro forma basis and based upon the number of Assure shares to be issued in the proposed Merger, current Danam stockholders are expected to own approximately 90% of the combined company and current Assure stockholders are expected to own approximately 10% of the combined company, in each case subject to certain adjustments in the Merger Agreement, and resulting in a combined publicly traded company valued in the Merger Agreement at approximately $150 million on a fully diluted basis. The boards of directors of both companies have unanimously approved the Merger Agreement. The Merger is expected to close in the second quarter of 2024, subject to satisfying certain closing conditions, including the completion of certain acquisitions by Danam, a sale of assets by Assure, the receipt of shareholder approval by both companies and approval for listing of the combined company on Nasdaq. Upon closing of the proposed merger, Suren Ajjarapu will serve as Chairman of the combined company. The Merger Agreement provides that the Board of Directors of the combined company will comprise of five members designated by Danam.

10:00 EST New York Community Bancorp rises 7.9% - New York Community Bancorp is up 7.9%, or 39c to $5.29.

10:00 EST VF Corp. rises 8.6% - VF Corp. is up 8.6%, or $1.31 to $16.61.

10:00 EST Manchester United falls -8.3% - Manchester United is down -8.3%, or -$1.76 to $19.37.

09:53 EST Knightscope reports Las Vegas apartment complex renews ASR contract - Knightscope announces that a Las Vegas apartment complex has renewed its K5 Autonomous Security Robot contract for the fourth consecutive year.

09:47 EST Sunlands Online falls -4.8% - Sunlands Online is down -4.8%, or -43c to $8.50.

09:47 EST Big Lots falls -25.7% - Big Lots is down -25.7%, or -$1.38 to $3.98.

09:47 EST VF Corp. rises 5.5% - VF Corp. is up 5.5%, or 83c to $16.14.

09:44 EST Intelligent Bio Solutions Inc trading halted, volatility trading pause

09:36 EST XTI Aircraft Company receives expanded patent from China - XTI Aircraft Company announced that the China National Intellectual Property Administration has issued a new utility patent for the Company related to the TriFan 600, an innovative, fixed-wing, vertical takeoff and landing aircraft currently in development. Generally, the patent covers certain aspects of the TriFan's pivoting ducted fans that rotate between vertical lift and horizontal thrust, which, in turn, are designed to enable the TriFan 600 to transition from vertical takeoff to forward cruise. XTI previously announced a merger agreement with Inpixion.

09:33 EST NY Governor visits Belden's Syracuse facility, announces $2.4M in incentives - Belden last week welcomed New York Governor Kathy Hochul to its Syracuse, NY, facility where the governor announced $2.4 million in incentives and tax credits to expand fiber production at the company's Central New York site. Syracuse is home to Belden's primary Broadband Solutions location, operating under the PPC Broadband brand, where Hochul highlighted key programs in her 2024 New York state budget. The Governor also announced a flurry of economic and financial awards, including a $1.2 million Empire State Development grant for Belden and a $1.2 million Excelsior Jobs tax credit. Along with the economic incentives for Belden, Governor Hochul announced 18 additional recipients across New York State to receive a total of $15 million in financial awards through the Regional Economic Development Council initiative.

09:18 EST CymaBay jumps 24% to $31.91 after FDA grants priority review for seladelpar

09:15 EST Camber Energy announces milestone with carbon-capture technology - Camber Energy shared the announcement from ESG Clean Energy,advising the results of recent testing of ESG's patented water removal system at its active power generation site in Holyoke, MA, were consistent with and/or exceeded ESG's modeled forecasts and confirms, according to ESG, capturing carbon dioxide can now be achieved at a low cost and in an energy-efficient manner utilizing ESG Clean Energy's technology. Camber, through its subsidiary, has licensed the ESG Clean Energy System, which includes an intellectual property portfolio of nine patents, for exclusive use in all of Canada, and for multiple locations in the U.S.

09:12 EST Sigma Additive Solutions announces Special Meeting of Stockholders - Sigma Additive Solutions will hold a special meeting of stockholders virtually, via live webcast on Friday, March 8, 2024, at 10:00 a.m. Mountain Time to approve the Company's name change to "NextTrip, Inc." and an amendment to the Company's charter to increase the number of authorized shares of the Company's common stock. The purpose of the Special Meeting is to consider and vote upon: The approval of an amendment to our Amended and Restated Articles of Incorporation, as amended, to change the Company's corporate name to "NextTrip, Inc." The approval of an amendment to our Charter to increase the authorized shares of our common stock from 1,200,000 shares to 250,000,000 shares; and The adjournment of the Special Meeting by the chairman thereof to a later date to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes to approve the Name Change Proposal or the Capital Increase Proposal.

09:08 EST Infinite Reality completes acquisition of Ethereal Engine - Infinite Reality and Ethereal Engine have completed a share-for-share acquisition valuing Infinite Reality at $2.5 billion and Ethereal Engine at $75 million. This latest transaction provides yet another multi-billion-dollar valuation benchmark for Infinite Reality following the December 2023 partnership and equity swap with Greenidge Generation Holdings (GREE) and the proposed December 2022 go-public deal with Newbury Street Acquisition Corporation (NBST). Founded in 2020 by industry veterans Liam Broza, Kyle Baran, Gheric Speiginer, Josh Field, David Gordon and Griffin Rowell, Ethereal Engine is the most advanced 3D web engine with an open core, making it a new type of competitor to proprietary game engines capable of personal world-building, allowing users to "build experiences once and run them everywhere." Ethereal has optimized its designing services for unparalleled, device-agnostic, immersive and enterprise-scale commercial experiences through a web browser rather than a downloaded client. Built on popular Javascript structures, Ethereal uses end-to-end frameworks for the web to build scalable multiplayer infrastructures for both games and social experiences, complete with voice, video, expressive avatars and a dedicated visual editor. These are then able to be implemented and navigated across desktop and mobile devices including wearable technology such as Apple's Vision Pro and Meta's Quest 2. Ethereal's existing client roster includes T-Mobile, Johnson & Johnson, Ripple, LAX, Refactor Games and Arc Media. With its extensive experience designing and creating digital worlds and virtual spaces with unparalleled user interfaces, Ethereal is able to seamlessly integrate into Infinite Reality's existing product offerings, enabling brands to further engage through content creation, paid media, marketing, customer relationship building and monetization, and more. As part of the deal, the two companies engaged in a share-for-share exchange and Infinite Reality will integrate all of Ethereal Engine's business units, technology products and personnel.

09:07 EST BlackLine names Sumit Johar as chief information officer - BlackLine announced that Software-as-a-Service and intelligent automation industry veteran Sumit Johar has joined the company as chief information officer, effective Feb. 12th. Reporting to Co-CEO Therese Tucker, Johar will oversee Information Technology and Information Security globally for the digital finance transformation leader. Johar comes to BlackLine with more than 20 years of enterprise cloud experience spanning applications, infrastructure, cybersecurity, data governance and engineering, and automation. He most recently served as CIO at Automation Anywhere, a provider of AI-powered intelligent automation solutions.

09:06 EST Stellantis adopts SAE standard connector to expand EV charging options - Stellantis brands' battery-electric vehicles - BEVs - in North America will adopt the proposed SAE J3400 connector, starting with select models in 2025. During the transition period, Stellantis will also make adapters available for vehicles fitted with the Combined Charging System port, enabling drivers to access a growing private and public J3400 infrastructure to meet J3400/1 requirements still being developed this year. This expands charging options for Stellantis customers. Stellantis has joined with six other automakers to develop a high-powered charging network with at least 30,000 charge points in urban and highway locations across North America by 2030. Charging stations will be accessible to all BEV customers, offering both Combined Charging System and J3400 connectors natively. The first charging stations from this joint venture are expected to open in 2024.

09:05 EST Kintara Therapeutics initiates REM-001 15-patient clinical trial - Kintara Therapeutics announced the initiation of a REM-001 15-patient clinical trial in cutaneous metastatic breast cancer patients. This open label 15-patient study in CMBC patients is evaluating REM-001, a second-generation photodynamic therapy photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate of the target treatment fields at any time from treatment up to, and including, week 24.

09:03 EST Heart Test Laboratories appoints Strom to Scientific Advisory Board - Heart Test Laboratories announced the appointment of Jordan Strom M.D., M.Sc., to its Scientific Advisory Board. Dr. Jordan Strom is Director of the Echocardiography Laboratory and Director of Echocardiographic Research at Beth Israel Deaconess Medical Center in Boston, Massachusetts; Assistant Professor of Medicine at Harvard Medical School, and Section Head for Cardiovascular Imaging Research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.

09:02 EST Kingswood Capital acquires Progress Lighting from Hubbell, no terms - Kingswood Capital Management announced that it has acquired Progress Lighting from Hubbell. Progress Lighting is a source for residential and light commercial decorative lighting solutions. As part of the transaction, Kingswood has partnered with the company's existing management team. Headquartered in Greenville, SC, Progress Lighting has distribution centers located throughout the country that support one of the largest networks of homebuilders, lighting showrooms, electrical contractors, home centers, and ecommerce retailers in the United States and Canada.

09:02 EST Fat Brands' Marble Slab Creamery announces 40-unit development deal - FAT announces a new development deal set to open 40 new Marble Slab Creamery franchised locations throughout Canada in partnership with Canadian Ice Cream Company Inc. The Marble Slab Creamery locations are set to open over the next 10 years, with the first of the new locations slated to open by the end of 2024. The development deal will bolster the brand's presence from approximately 100 stores that are operating today in the country to 140 units. "We are very pleased with the continued market growth in Canada with our experienced master franchise partner, Canadian Ice Cream Company Inc.," said Taylor Wiederhorn, Chief Development Officer of FAT Brands. "Since entering the country nearly 20 years ago, Marble Slab Creamery has made a name for itself. Our homemade ice cream and unlimited mix-in philosophy resonate with fans and our franchisees as we continue to expand the concept across Canada and the world."

09:00 EST Applied Digital says Ellendale facility suffered complete outage, remains down - In a regulatory filing after the market close on Friday, Applied Digital disclosed: "On January 18, 2024, we began experiencing a power outage at our Ellendale datacenter hosting facility, resulting in a complete outage by January 19, 2024. This complete power outage is currently ongoing as our electricity provider is performing upgrades to ensure stability of our electrical supply. The financial impact of the outage was unknown at the time it occurred. Management has since been able to assess this matter and, as of February 6, 2024, has determined that revenues from this facility will be materially impacted by this outage for the quarter-ending February 29, 2024; however, management cannot be certain of the exact amount of that impact at this time. Management expects this facility to be online again during February 2024."

08:52 EST WTW enters co-brokerage agreement Solomon Agency Corporation - WTW announced a co-brokerage arrangement with the Solomon Agency Corporation. Focusing on insurance brokerage, risk management and related services, the agreement is intended to align resources to deliver industry-leading brokerage support and customized insurance solutions to North American exposures of companies with Headquarters in South Korea and Vietnam.

08:43 EST Rail Vision announces AI-based computer to enhance railway safety - Rail Vision has introduced its next generation AI-based computer designed enhance railway safety and prevent accidents. This advanced technology marks a significant step forward in the realm of railway safety, leveraging artificial intelligence to detect potential hazards and mitigate risks effectively. The new AI-based computer from Rail Vision, previously announced, incorporates advanced artificial intelligence algorithms, enabling it to analyze vast amounts of data in real-time. By processing information from various sensors and cameras installed on trains, the AI-based computer can accurately identify obstacles, track infrastructure conditions, and detect potential dangers along the railway tracks. This proactive approach empowers railway operators to take timely actions to prevent accidents and ensure the safety of passengers and personnel. Rail Vision's new AI solution will be seamlessly integrated into both their Main Line and Switch Yard systems, revolutionizing safety measures across all aspects of railway operations.

08:41 EST WisdomTree reports current total AUM $100.3B as of January 2024 - WisdomTree released monthly metrics for January 2024, including assets under management AUM and flow data by asset class...Robust ~$1 B of net inflows generated a 21% pace of YTD organic growth across the equity franchise...Positive fee impact from strong flows into a mix of high fee funds such as Japan Hedged Equity Fund , India Earnings Fund EPI and U.S. Quality Dividend Growth Fund outpace outflows in Floating Rate Treasury Fund...WisdomTree currently has approximatelyWisdomTree currently has approximately $100.3 billion in assets under management globally.

08:40 EST Vicinity Motor secures follow-on order for 12 Vicinity Classic buses - Vicinity Motor announced the receipt of a follow-on purchase order from Autobus La Quebecoise for twelve Vicinity Classic buses to service the cities of La Prairie, Candiac, Saint-Philippe, Delson, Saint-Constant and Sainte-Catherine in Quebec. Per the terms of the supply agreement, Autobus La Quebecoise has ordered an additional twelve of the Company's 32-foot Vicinity Classic clean-diesel buses for delivery in 2025. Autobus La Quebecoise is part of Groupe La Quebecoise, which consists of approximately twenty companies offering various types of transportation services, including school bus, municipal, paratransit, shuttle, intercity, charter, helicopter, residual materials pick-up, executive aircraft charter, regional airline service and aeromedical evacuation. The business operates primarily in Quebec, but its service extends into other parts of Canada as well as the United States.

08:39 EST Pharma company selects ARIA Cybersecurity's AZT PROTECT solution - ARIA Cybersecurity Solutions announced that one of the world's largest pharmaceutical manufacturers has selected ARIA Cybersecurity's AZT PROTECT solution to protect its critical infrastructure from a new wave of sophisticated cyberattack. The US-based multinational corporation, a Fortune-500 company with billions of dollars in annual revenue, in a multi-million dollar deal will deploy AZT PROTECT across its global manufacturing, protecting over 40 facilities in response to the growing cybersecurity threat to operational technology from hostile nation states, terrorism, and organized cybercrime.

08:37 EST Gilead to acquire CymaBay for $32.50 per share in cash - Gilead (GILD) and CymaBay (CBAY) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3B. The company said the addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients. The transaction was approved by both the Gilead and CymaBay Boards of Directors and is anticipated to close during the first quarter of 2024, subject to regulatory approvals and other customary closing conditions. Under the terms of the merger agreement entered into in connection with the transaction, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of CymaBay's common stock at a price of $32.50 per share in cash, which offer price represents a 27 percent premium to CymaBay's closing share price on February 9, 2024. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer. Upon FDA approval of seladelpar, the proposed transaction is expected to enhance Gilead's revenue growth, and it is also expected that the transaction will be approximately neutral to earnings per share in 2025 and significantly accretive thereafter. Consummation of the tender offer is subject to a minimum tender of at least a majority of then-outstanding CymaBay shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

08:35 EST ABVC BioPharma receives Australian patent for treatment of MDD - ABVC BioPharma received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder. The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment. The patent application was submitted to the Australian Patent and Trademark Office under "Polygala Extract for the Treatment of Major Depressive Disorder." The invention relates to oral administration of the formulation containing a Radix Polygala extract, PDC-1421, as a capsule for treating Major Depressive Disorder. Based on the Company's current internal studies, administering the composition should be done over at least 25 days, with the daily dose varying once, twice, or three times per day; each dose ranges between 380-760 mg of the botanical extraction. ABV-1504, the Company's asset indicated for use in MDD containing PDC-1421, is a botanical-based Norepinephrine Transporter inhibitor that has completed Phase II clinical studies, with plans to initiate an End of Phase II meeting with the FDA. The CNS drugs with the indications of MDD and ADHD have been valued globally at $667M by a third-party valuation company and licensed to AiBtl BioPharma on November 12, 2023 by entering into a definitive global licensing agreement. According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment. The Company expects AiBtl to achieve the further milestones under the agreement, upon which the Company may receive the remaining licensing fees of up to $7M cash and 5% royalties of net sales, up to $200M.

08:34 EST Verb Technology announces launch of Frankie Avalon's shopping show - Verb Technology Company announces the launch of an extraordinary livestream shopping series on MARKET.live featuring Frankie Avalon and co-hosted by the popular TV personality Albany Irvin. The show, the first in a series, is scheduled for Thursday, February 15, at 3 pm PST / 6 pm EST.

08:33 EST Cooper-Standard names Alison Nudd as chief accounting officer effective March 1 - Cooper Standard announced the promotion of Alison Nudd to vice president, chief accounting officer, effective March 1. She replaces Amy Kulikowski who is departing the Company to pursue other career opportunities. Nudd most recently served as vice president, global internal audit and compliance where she provided leadership, strategy and planning for Cooper Standard's global internal audit and compliance activities, including the company's Sarbanes-Oxley program and enterprise risk management efforts.

08:33 EST NRx Pharmaceuticals receives $5M milestone payment - NRx Pharmaceuticals announced the advance of the first $5M milestone payment based on the company's partnership agreement with Alvogen and Lotus Pharmaceutical. Under the terms of the updated agreement, the company will immediately receive $5M of the first milestone, which NRx will use to fund development of NRX-101 through the phase 2 meeting with FDA. As compensation for advancing the milestone, Alvogen and Lotus will receive 4.1 million warrants to purchase the company's common stock, at a strike price of 40c with a 3 year term. The second portion of the milestone will be $4M and, as before, be triggered by a positive response to the company's planned end of phase 2 meeting with FDA. NRx then remains eligible to receive up to $320M in future development and sales milestones, as well as royalty payments escalating to mid-teen percentages on Net Sales, subject to achievement of certain sales volumes. Additionally, Alvogen and Lotus will be responsible for future development and commercialization costs for NRX-101 in treatment of bipolar depression with suicidality.

08:32 EST InterDigital appoints Kaskoun as Chief Growth Officer - InterDigital announced that Ken Kaskoun has been appointed as the company's Chief Growth Officer, reporting to Liren Chen, President and Chief Executive Officer of InterDigital. Prior to SomaLogic, Ken spent 15 years at Qualcomm (QCOM) in various IP-related roles, most recently as Vice President of the Strategy and Analysis team in Qualcomm Technology Licensing

08:31 EST Corvus Pharmaceuticals presents preclinical data for soquelitinib - Corvus Pharmaceuticals announced that preclinical data for soquelitinib, the Company's lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024. The poster presentation includes the first description of Corvus' next-generation ITK inhibitor preclinical product candidates, which were designed to deliver precise T-cell modulation that is optimized for specific immunology indications. These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function. "We have established our leadership in ITK inhibition with the development of soquelitinib, which is advancing on track towards the initiation of a registration Phase 3 trial in relapsed peripheral T cell lymphoma and the initiation of a randomized, placebo-controlled Phase 1 trial in atopic dermatitis," said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "We are building further on the connection between lymphoma and immune diseases, and the role of ITK inhibition. Our research has led to the development of next-generation inhibitors that are designed to precisely modulate specific T cell subset functions in order to potentially treat a range of diseases. The selectivity of these next generation ITK inhibitors gives Corvus options to choose between broad immunosuppression and highly targeted immunomodulation depending on the clinical indication."

08:23 EST National Energy Services launches key technologies, provides operational update - National Energy Services Reunited announced the launch of key technologies and provided an operational update during the International Petroleum Technology Conference in Saudi Arabia. Following the opening of IPTC by HRH Prince Saud Bin Nayef Bin Abdul-Aziz Al Saud and HRH Prince Abdulaziz Bin Salman Bin Abdul-Aziz Al Saud, NESR launched its Roya advanced drilling platform and its NESR Environmental & Decarbonization Applications segment, which encompasses a growing portfolio of solutions that were previously launched under NESR ESG Impact. Sherif Foda, Chairman & CEO commented, "We are honored to launch our key strategic technologies during the prestigious IPTC held in Dhahran and hosted by our esteemed customer, Aramco. Our ROYA platform of advanced drilling technologies, comprised of a rotary steerable RoyaSteer, measurement-while-drilling tool RoyaStream, and logging-while-drilling tool RoyaSeek, paves the way for NESR to participate in all high-end drilling opportunities. Additionally, our new segment NEDA, translated from Arabic as "call to action", signifies our belief that decarbonization of the sector is fundamental to the success of the energy industry. Following our initial start back in Riyadh during FII in 2021, we have made great progress with the recent inauguration of a Carbon-Light Brine facility in Iraq, and also in completing two successful water zero liquid discharge projects with Aramco. Now is the time to pursue scalable projects across all NEDA subsegments, including water treatment, flare management, heat capture, and emissions detection. We are very excited about the future of the company and the richness of our portfolio in both core businesses and in our decarbonization efforts."

08:20 EST Tilt Holdings' Jupiter Research introduces THREDZ - TILT Holdings, in tandem with its subsidiary Jupiter Research, announced the mass market launch of a new patented, stackable 510 technology-THREDZ. THREDZ is a stackable cartridge that prioritizes portability and personalization, allowing consumers to blend two oil cartridges. "THREDZ is the result of our continuous efforts to best serve brands and their consumers through access to innovative technology that offers new and unique experiences," said TILT Chief Executive Officer, Tim Conder. "Today's cannabis enthusiasts are looking for customizable consumption, and THREDZ allows them to combine different oils to create the perfect, personalized smoke session. Through Jupiter Research, TILT offers a diverse, inhalation-led product portfolio to consumers across the U.S. and abroad."

08:19 EST Smith & Nephew unveils expanded sports medicine portfolio - Smith+Nephew announces the premiere of its newly acquired CARTIHEAL AGILI-C Cartilage Repair Implant alongside the REGENETEN Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. "As a leader in Sports Medicine, we are committed to bringing emerging technologies that address unmet clinical needs to our customers and their patients," said Scott Schaffner, President Sports Medicine, Smith+Nephew. "Both REGENETEN and CARTIHEAL AGILI-C implants have the opportunity to set new benchmarks for standard of care across multiple joint repair indications and deliver better patient outcomes."

08:17 EST 4D Molecular presents interim data from 4D-310 INGLAXA Phase 1/2 trials - 4D Molecular Therapeutics announced updated interim safety and efficacy data on six adults with Fabry disease cardiomyopathy treated with a single intravenous infusion of 4D-310 with follow-up of 12-33 months overall, including 12-24 month follow-up data on cardiac contractility, exercise capacity, quality of life and cardiac biopsy data. The data was presented in a late-breaking session at WORLDSymposium 2024 in San Diego, California on Friday, February 9, 2024. INGLAXA Phase 1/2 Clinical Trial Design & Enrollment: Dose escalation and dose expansion trial assessing a single IV infusion of 4D-310 in a broad and diverse Fabry disease patient population; Enrolled six patients, each treated with 1E13 vg/kg of 4D-310 and a prophylactic corticosteroid immunosuppressive regimen; Protocol amended to change immunosuppressive regimen to rituximab and sirolimus; Cardiac biopsies allowed at week 6 and 26 in the INGLAXA-2 trial. INGLAXA Phase 1/2 Interim Data Summary: Safety and Tolerability: Previously reported cases of aHUS have fully resolved; No clinically significant cardiac or liver toxicities; No new 4D-310-related adverse events greater than Grade 1 since the last interim update in February 2023. Echocardiography Contractility Assessments: Improved GLS in all five evaluable patients by month 12; Two patients who reached 24 months of follow-up both showed clinically meaningful improvement with change from baseline exceeding the minimal detectable difference of -1.5%. Cardiopulmonary Exercise Testing Peak VO2 Assessments: 3 of 4 evaluable patients demonstrated clinically meaningful improvement by CPET peak VO2 with change from baseline exceeding the minimal clinically important difference of +1.5 at month 12; One patient who reached 24 months of follow up continued to show meaningful improvement with change from baseline exceeding the MCID of +1.5. Cardiac Quality of Life Assessments; Two patients had low baseline scores less than90; both patients had clinically meaningful improvements in QOL; Cardiac Biopsy Assessments of Transgene Expression and Substrate Clearance; Cardiac biopsies at week 6 and 26 from one patient showed robust & durable 4D-310-mediated transgene expression in cardiomyocytes: At week 26, mean Gb3 inclusion body volume per cardiomyocyte was reduced 15% from week 6 and 61% vs. historical sample collected approximately 7 years prior to enrollment and analyzed independently by investigator.

08:13 EST SP Plus stockholders approve merger with Metropolis Technologies - SP Plus Corporation announced that at its special meeting of stockholders held on February 9, 2024, SP+ stockholders voted to approve the previously announced Agreement and Plan of Merger, dated as of October 4, 2023, by and among Metropolis Technologies, Schwinger Merger Sub Inc., a direct, wholly owned subsidiary of Metropolis and SP+, pursuant to which Merger Sub will merge with and into SP+, with SP+ surviving the Merger as a wholly owned subsidiary of Metropolis. At the Special Meeting, approximately 99.94% of the votes cast were voted in favor of the proposal to adopt the Merger Agreement, which represented approximately 78.64% of the outstanding shares of SP+'s common stock entitled to vote thereon. Under the terms of the Merger Agreement, SP+ stockholders will be entitled to receive $54.00 per share in cash, without interest and subject to any required tax withholding, at the closing of the Merger. Approval by SP+'s stockholders satisfies one of the conditions necessary for completion of the Merger. The Merger remains subject to the satisfaction or waiver of certain other closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

08:12 EST Banzai signs over 220 corporate customers in January - Banzai International announces the Company's successful customer acquisitions efforts in January with the addition of over 150 new corporate customers to its impressive customer roster. "We are thrilled about our recent customer acquisition efforts and can't wait for what's to come in 2024, as we are adding more MarTech offerings to our integrated family of products. Our organic efforts are heavily supplemented by our acquisition targets that we expect will offer great cross-selling opportunities," said Joe Davy, CEO and Founder of Banzai. "I see Banzai well positioned to aggressively grow in 2024 and beyond."

08:11 EST Curtiss-Wright in subsea-less canned motor boosting system deal with Petrobras - Curtiss-Wright (CW) announced that it has signed a Technology Cooperation Agreement with PETROLEO BRASILEIRO S.A. - PETROBRAS (PBR) to design, manufacture, test, and provide operational support for a Subsea Canned Motor Boosting System, to be deployed mudline at a Petrobras production field in the Campos Basin, Brazil. Curtiss-Wright is working jointly with Petrobras to develop a subsea boosting system for unprocessed hydrocarbon fluid consisting of a mixture of oil, gas and particulates that will operate at a 1,500-meter water depth. The system will leverage Curtiss-Wright's canned motor technology, as well as Petrobras' expertise in flow assurance and offshore hydrocarbon production and processing, to ensure the subsea boosting system will perform according to field requirements. Further, it is expected to serve as an effective and reliable alternative to current subsea pump technologies by reducing unplanned outages and production interruptions. ." "We are excited to be working collaboratively with a leading technology developer and experienced end-user of downhole pumping and mudline boosting systems for demanding applications," said Lynn M. Bamford, Chair and CEO of Curtiss-Wright Corporation. "These efforts will allow us to apply our proven canned motor technology expertise to this adjacent market, thereby enabling an all-electric subsea production system, while providing an opportunity to bring tremendous value to Petrobras."

08:10 EST Invizyne files registration statement for proposed offering, listing on Nasdaq - Invizyne Technologies, a subsidiary of MDB Capital Holdings, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for the sale of its common stock in a firm commitment public offering. The offering shall be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million. Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol "IZTC." Public Ventures, LLC will be acting as the underwriter and sole book manager for the proposed offering. Digital Offering, LLC will be acting as the qualified independent underwriter. Public Ventures, LLC is a subsidiary of MDB and an affiliate of Invizyne. In allocating the shares to be sold, Public Ventures, LLC intends to give preference to holders of MDB Class A Shares, after which it will give preference to the other beneficial shareholders of MDB and then of Invizyne. To the extent these foregoing groups do not purchase all the available shares, including the overallotment, then shares will be sold to other persons making an indication for purchase of shares through their respective brokers or dealers.

08:09 EST CervoMed announces data from AscenD-LB phase 2a trial - CervoMed announced that data from the AscenD-LB Phase 2a trial evaluating treatment with neflamapimod in patients with dementia with Lewy bodies were published online in the Journal of Prevention of Alzheimer's Disease. The published manuscript titled "Phase 2a learnings incorporated into RewinD-LB, a Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies," is available online. Results published for the first time in the JPAD manuscript are as follows: An integrated summary of the effects of neflamapimod 40mg three-times-a-day compared to placebo in the AscenD-LB Phase 2a clinical trial across all endpoints in the overall patient population that contains a mixed population of patients with DLB with evidence of AD and patients with pure DLB; and in the pure DLB patient population alone. EEG results from the AscenD-LB Phase 2a trial, which demonstrated that neflamapimod 40mg TID treatment led to improvement in beta functional connectivity assessed by EEG. In a prior Phase 2a study in AD, neflamapimod treatment led to an increased volume and functional connectivity of the basal forebrain by MRI. Specifically, the analysis demonstrated that the volume of the nucleus basalis of meynert was higher at the end of 12 weeks neflamapimod treatment. Treatment with neflamapimod was also associated with higher functional dynamic connectivity between the NbM and deep grey matter at EOT.

08:08 EST Kratos Defense receives $877M multiple-award IDIQ contract - Kratos Defense & Security Solutions announced that its Kratos Space & Missile Defense Systems Inc., business unit has received a multiple-award, indefinite-delivery/indefinite-quantity, cost-plus-incentive-fee, cost-plus-fixed-fee, and firm-fixed-price contract with a combined maximum ceiling of $877 million with a nine-year ordering period for Sounding Rocket Program-4. This contract provides suborbital launch services and launch support services necessary to accomplish the Rocket Systems Launch Program's suborbital mission. The primary locations of performance of the work will be at the contractor facilities and a variety of government launch sites, depending on mission requirements, and is expected to be completed by November 15, 2029. This contract was a competitive acquisition, and three offers were received. Space Systems Command, Kirtland Air Force Base, New Mexico, is the contracting activity.

08:07 EST Daxor announces two significant customer transactions with BVA-100 - Daxor Corporation announces two significant new customer transactions with Daxor's BVA-100 in January, marking a strong start to 2024. New wins include: Four-year lease agreement for the BVA analyzer at an award-winning network of 24 affiliated hospitals in Mississippi, West Tennessee, and East Arkansas with a reach into Kentucky, Missouri, and central Alabama; BVA analyzer purchase at a 200-bed independent hospital in Mississippi. "Our sales and marketing teams have kicked off the new calendar year with great momentum," said Michael Feldschuh, Daxor's CEO and President. "We remain focused on commercialization - broadening our reach with new analyzer purchases, and driving utilization within our current customer base, supported by our ezBVA Lab service."

08:06 EST Potbelly announces three-year $30M credit facility - Potbelly Corporation closed a new $30 million revolving credit facility that matures on February 7, 2027 led by Wintrust Bank. Under the terms of the new Facility, the Company achieved a 600-basis point reduction in the currently applicable interest rate margin relative to the prior term loan. The Facility currently bears an interest rate of SOFR + 325 basis points with the potential applicable interest rate ranging from SOFR + 375 basis points to SOFR + 275 basis points dependent upon certain leverage ratios achieved by the Company. The new Facility is expected to result in approximately $2 million of annual net cash interest savings.

08:05 EST FDA approvesTakeda's Eohilia for eosinophilic esophagitis treatment - Takeda announced that the U.S. Food and Drug Administration FDA has approved EOHILIA or budesonide oral suspension , the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis EoE .1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February. EOHILIA is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older with EoE.1 Developed specifically for EoE, EOHILIA's novel formulation of budesonide confers thixotropic properties - flowing more freely when shaken and returning to a more viscous state when swallowed. "Various formulations of corticosteroids have been used in the past to manage EoE, but in an off-label capacity and using multiple delivery options. With EOHILIA, it's gratifying to now have an FDA-approved treatment specifically formulated for a consistent dose delivery with demonstrated ability to address esophageal inflammation and EoE dysphagia symptoms," said Ikuo Hirano, MD, professor of medicine and director of the Kenneth C. Griffin Esophageal Center in the Division of Gastroenterology and Hepatology at Northwestern University Feinberg School of Medicine. "As the treatment needs and goals of patients with EoE can vary, I welcome the flexibility that EOHILIA offers as an oral medication."

08:05 EST BranchOut Food expands relationship with nation's largest retailer - BranchOut Food announced that it has expanded its relationship with the nation's largest retailer. The new agreement is valued at an estimated $7.6 million annually. BranchOut has renewed its contract with the retailer for two products and entered into a new contract for two additional products. The company received a 12-month contract extension for two dried fruit private label items that were first supplied in 2023. The new contract is for two additional dried vegetable private label items. The order for approximately 3,300 stores is about 50% larger than initially expected and is valued at an estimated $2.6 million on an annual basis. Shipments are scheduled to begin in May 2024. Eric Healy, CEO of BranchOut Foods, said, "We're gratified that the first run of our products in the stores of the nation's largest retailer has resulted in this contract extension. We're especially excited to have received a new contract for two additional products, and for more stores than initially expected. Our private label business is an important growth engine for BranchOut, and these contracts with the nation's largest retailer are just the tip of the potential that we see for this business segment."

08:04 EST Tonix Pharmaceuticals announces FDA IND clearance for trial of TNX-102 SL - Tonix Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, has cleared the Investigational New Drug, IND, application for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL1 in reducing the severity of acute stress reaction and the frequency of acute stress disorder and posttraumatic stress disorder. The trial is sponsored by The University of North Carolina Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense. "No medication is currently available at or near the point-of-care to treat patients suffering from traumatic events and support long-term health," said Seth Lederman, M.D., Chief Executive Officer of Tonix. "There is an unmet need for treating ASR after traumatic events such as civilian motor vehicle collisions or warfighter experiences in forward bases or in theater. Previous trials of TNX-102 SL in PTSD suggested activity on sleep and stress related symptoms in the first several weeks of treatment.2,3 The study is motivated by the observation that the symptoms of ASR and PTSD are similar and by the hypothesis that TNX-102 SL's effect on sleep quality may reduce ASR symptoms."

08:02 EST Jack Henry raises quarterly dividend 6% to 55c per share - The cash dividend on its common stock is payable on March 26 to stockholders of record as of March 8. Jack Henry has paid consecutive quarterly dividends since 1991, and 2023 marked the 20th consecutive year of an increasing dividend.

07:49 EST Save Foods board decides to distribute Plantify holdings later in 2024 - Save Foods board of directors agreed to authorize the Company's officers to begin preparing a distribution plan of Save Foods' holdings in Plantify Foods, which the Company believes will launch later in 2024. As of the current date, Save Foods currently holds 85,008,698 Common Shares of Plantify, representing 23.1% of the total number of issued and outstanding Common Shares of Plantify. The contemplated distribution remains subject to obtaining the requisite legal opinion and regulatory approvals, if and as needed

07:47 EST Ormat Technologies secures approval for PPA amendments - Ormat Technologies (ORA) announces Hawai'i Public Utilities Commission's approval of two final amendments to the Power Purchase Agreement between its subsidiary, Puna Geothermal Venture, and Hawaiian Electric (HE). This landmark decision enables PGV to contribute up to an additional 8 megawatts of clean, dispatchable renewable power to Hawai'i Island, elevating the contract maximum capacity to 46 MW, with a minimum contracted capacity set at 30 MW. The approval follows PGV's completion and submission of its final Environmental Impact Statement for operations in Puna, Hawai'i. The EIS was a condition set by the HPUC for approval of an amended and restated PPA that was submitted to the HPUC in December 2019. The newly amended and restated PPA consolidates two existing agreements into one contract with a term extending through 2052. Notably, the approval guarantees fixed energy rates, de-coupled from oil prices, which ensures PGV with a stable revenue stream, and benefits ratepayers with fixed energy costs across the term of the contract. As part of this agreement, older generation units will be decommissioned and replaced with three cutting-edge, efficient generating units from Ormat. The new PPA will be in effect following the operation of the new state-of-the-art units that are scheduled to be operational within three years post-HPUC approval.

07:40 EST AbbVie completes the acquisition of ImmunoGen - AbbVie (ABBV) announced that it has completed its acquisition of ImmunoGen (IMGN). With the completion of the acquisition, ImmunoGen is now part of AbbVie. AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen's common stock will cease to trade on the NASDAQ stock exchange prior to market open on February 12. AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term.

07:36 EST Abacus Life prices $25M public offering of 9.875% notes - Abacus Life has priced an underwritten public offering of $25 million in aggregate principal amount of its additional 9.875% notes due 2028. The New Notes will have the same terms as, will be fully fungible with and will be treated as a single series of debt securities as, the 9.875% notes due 2028 the Company issued on November 10, 2023 in an aggregate principal amount of $35,650,000. When issued, the New Notes will bring the aggregate amount of Notes outstanding to $60,650,000. The Company has granted the underwriters an option to purchase up to an additional $3,750,000 in aggregate principal amount of New Notes solely to cover overallotments, if any. The offering is expected to close on February 15, 2024, subject to customary closing conditions. Piper Sandler & Co., A.G.P. / Alliance Global Partners, and Ladenburg Thalmann & Co. Inc. are serving as joint book-running managers for the offering. The Company expects to use the net proceeds from this offering to refinance other outstanding indebtedness and for general corporate purposes. Locke Lord LLP acts as legal counsel to the Company, and Alston & Bird LLP acts as legal counsel to the underwriters.

07:34 EST Fairfax Financial 'categorically' denies all Muddy Waters allegations - The management team of Fairfax Financial Holdings has now reviewed all the 72 pages of the Muddy Waters report and reviewed its allegations and insinuations. The company said, "We categorically deny and refute all of them, without exception, as false and misleading. To the best of our knowledge, Muddy Waters has never attended our conference calls and never asked a question, called us or written to us, but instead went to CNBC during our quiet period with these one-sided, ill-informed allegations and insinuations in a transparent attempt to profit by short selling our stock. They may have successfully done this with other companies, but they have woefully misjudged the strength of Fairfax's financials and prospects and we are confident the marketplace will reflect our strong fundamentals." Prem Watsa, Chairman and CEO of Fairfax, commented: "We are neither Berkshire Hathaway, nor GE, as Muddy Waters suggests. We are Fairfax, a strong and enduring company built over 38 years, committed to integrity, customer service, employee welfare and the communities we operate in. We have a unique Fair and Friendly culture throughout our organization. We strive to provide excellent returns to shareholders, and are committed to providing full disclosure in our annual report, highlighting both our pluses and minuses. We have always been focused on building for the long term and have never given any quarterly guidance. Over 38 years, our book value per share has compounded by 18.9% per year and our stock price at 18.0% per year. Out of 6,000 companies listed in the U.S. in 1985, when we began, less than 20 companies have a similar record. We have discussed repeatedly in our annual reports that we have not achieved our 15% objective in the last 5 to 10 years. However, we have more than achieved our 15% return over the last several years. Moreover, as those following Fairfax more closely are aware, the foundation of our operating income is stronger than ever, and bodes well for the future. Our company is very strong and the best is yet to come. We look forward to answering any questions in our conference call on Friday, February 16, 2024 at 8:30 a.m. ET."

07:32 EST Anixa Biosciences begins dosing in second cohort of ovarian cancer CAR-T trial - Anixa Biosciences has commenced treatment for the fourth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. The first-in-human trial is enrolling patients with recurrent/resistant ovarian cancer who have progressed on at least two prior therapies. The CAR T was safe and tolerable in the first three patients treated. The fourth patient, the first patient enrolled in the second cohort, received triple the dose of CAR-T cells compared with the dose of the first cohort. Anixa's Follicle Stimulating Hormone Receptor -mediated CAR-T technology, also known as chimeric endocrine receptor T-cell, differs from traditional CAR-T therapy by targeting FSHR, which research indicates is expressed on ovarian cells, as well as in the vasculature of tumors.

07:31 EST Zimmer Biomet signs Global Health Equity Network's Zero Health Gaps Pledge - Zimmer Biomet signed the Global Health Equity Network's Zero Health Gaps Pledge, a commitment from CEOs across industries and regions for their organizations to embed health equity in core strategies, operations and investments. Zimmer Biomet's Health Equity division, established in 2023, has made meaningful strides on core areas of the 10-point pledge, including understanding the drivers of disparity in orthopaedic care, forging partnerships to collaborate on community-based solutions to reduce healthcare inequities, and establishing clear measures to track progress against short and long-term goals. Zimmer Biomet has a well-established legacy of addressing healthcare disparities through its philanthropic efforts, and now its Health Equity division has been working to integrate health equity goals into the company's business strategy.

07:28 EST Allied Properties, partners to reorganize ownership of TELUS Sky - Allied Properties Real Estate Investment Trust (APYRF) is working with its partners to reorganize the ownership of TELUS Sky in Calgary. TELUS Sky is the outcome of a development project undertaken by a joint-venture of three equal partners, TELUS (TU), Westbank and Allied. It is comprised of 452,352 square feet of office GLA, 13,059 square feet of retail GLA and 156 underground commercial parking and fleet stalls, as well as 326 rental residential units, related common areas and facilities and 176 underground residential parking stalls. TELUS is the anchor tenant of the Commercial Component, Westbank is the developer of the project and manager of the Residential Component and Allied is the manager of the Commercial Component. The reorganization will involve Westbank and Allied selling their respective 1/3 interests in the Commercial Component to TELUS and TELUS selling its 1/3 interest in the Residential Component to Westbank and Allied in equal shares, with the result that TELUS will own 100% of the Commercial Component and Westbank and Allied will own 100% of the Residential Component in equal shares.

07:22 EST Wearable Devices, Qualcomm collaborate to elevate XR experiences - Wearable Devices (WLDS) announced a collaboration agreement with Qualcomm Technologies (QCOM). This collaboration will help those looking to use Wearable Devices' innovative Mudra technology when developing products using the Qualcomm Snapdragon Spaces XR Developer Platform, redefining interaction in augmented reality and virtual reality environments. The Mudra technology, known for its touchless control capabilities, has been optimized to work with Snapdragon Spaces, enhancing the user experience with intuitive, gesture-based interactions.

07:17 EST BioXcel receives Fast Track designation from FDA for BXCL701 - BioXcel Therapeutics announced that the U.S. Food and Drug Administration has designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer with progression on chemotherapy and no evidence of microsatellite instability. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review.

07:15 EST Wabtec wins door and HVAC contract for Norske Tog's trains - Wabtec (WAB) won a major order to supply sustainable heating, ventilation, and air-conditioning HVAC units and efficient door systems for Norway-based Norske Tog's new regional trains. The new doors and Green Air HVAC systems provide the customer with improved cost savings, efficiency, sustainability, and an enhanced passenger experience. The company will supply the components to Alstom (ALSMY), which won a contract to deliver up to 200 Coradia Stream(TM) regional trains to Norske Tog. Wabtec will provide 180 saloon and 60 cab HVAC units for the first batch of trains, along with 720 door systems and gap fillers. First deliveries are expected in early 2024. Alstom will begin delivering the new trains to Norske Tog in 2025. Once in service, this new fleet will provide a suburban and fast rail service, connecting Ski and Stabekk in the greater Oslo region.

07:13 EST Allakos announces publication on AK006 mast cell inhibition - Allakos announced the publication of new scientific results in Allergy. The preclinical research found that AK006 impacts mast cell function by interacting with multiple activating receptors and key signaling molecules. The publication titled "Regulation of Mast Cells by Overlapping but Distinct Protein Interactions of Siglec-6 and Siglec-8" details efforts to identify proteins associated with Siglec-6 and Siglec-8 in mast cells and functionally characterize these protein interaction networks using ex vivo and in vivo models of mast cell activation. The data published today add to previously published preclinical data demonstrating that AK006 inhibits multiple modes of mast activation. As detailed in the Allergy publication, proteomic profiling of mast cells revealed Siglec-6 and Siglec-8 interact with a large cluster of proteins involved in IgE and non-IgE-mediated mast cell activation, including the high affinity IgE receptor, IL-4 and IL-33 receptors, and intracellular kinases LYN and JAK1. Importantly, Siglec-6 was found to interact with multiple critical regulatory proteins that do not interact with Siglec-8, including stem cell factor receptor KIT/CD117, different subunits of the FcRI receptor and proteins modulating metabolic processes. These findings suggest Siglec-6 has a broader role in regulating mast cell function and may contribute to the increased inhibitory effects observed with AK006 in vitro and in vivo.

07:12 EST Larimar reports topline data from Phase 2 dose exploration study of nomlabofusp - Larimar Therapeutics announced top-line data and completion of its four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with Friedreich's ataxia. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in frataxin levels in all evaluated tissues after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg and 50 mg cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Key Phase 2 Results: Median changes in FXN levels from baseline for the 25 mg and 50 mg cohorts of nomlabofusp; Skin cells: 2.81 pg/microgram for the 25 mg cohort and 5.57 pg/microgram for the 50 mg cohort; Buccal cells: 0.56 pg/microgram for the 25 mg cohort and 0.72 pg/microgram for the 50 mg cohort; As seen in our multiple ascending dose study, when dosing is switched to every other day, FXN levels decline from the levels achieved with daily dosing but remain above baseline. All treated patients demonstrated increases in FXN levels in skin cells and the majority of patients also demonstrated increases in FXN levels in buccal cells. At Day 14, all patients with quantifiable levels at baseline and Day 14 treated with 50 mg of nomlabofusp achieved FXN levels in skin cells greater than 33% of the average level found in healthy volunteers, and 3 of the patients achieved levels greater than 50% of the average healthy volunteer level. While FXN levels measured in buccal cells show a high degree of correlation with FXN levels measured in skin cells, higher variability in FXN levels was seen in buccal cells compared to skin cells in both the multiple ascending dose study and the Phase 2 dose exploration study. Skin cells have a lower turnover rate and skin is a more stable tissue. The collection method for skin cells is also well-established and standardized, which provides a more reliable and reproducible measure of changes in FXN levels with treatment compared to buccal cells. Median baseline tissue FXN levels in skin cells were 3.70 pg/microgram and 2.12 pg/microgram for the 25 mg and 50 mg cohorts, respectively, and in buccal cells were 1.78 pg/microgram and 1.61 pg/microgram for the 25 mg and 50 mg cohorts, respectively. Subjects who had one or more FXN measurements below quantifiable levels are excluded from the above analysis. For the placebo group, one participant had skin cell FXN levels below quantifiable levels on day 14 and day 28. For the 25 mg group, Day 14 and 28 skin biopsies were not collected from one nomlabofusp treated participant who discontinued treatment and one nomlabofusp treated participant had FXN levels below quantifiable levels at day 14 and day 28. For the 50 mg group, one participant had skin cell FXN levels below quantifiable levels at baseline. Subjects who had one or more FXN measurements below quantifiable levels are excluded from the above analysis. For the placebo group, one participant had buccal cell FXN levels below quantifiable levels at baseline and four participants had buccal cell FXN levels below quantifiable levels at day 14 and day 28. For 25 mg group, day 28 buccal FXN were not collected from one participant who discontinued treatment and two participants had buccal FXN levels below quantifiable levels at baseline. For the 50 mg, one participant had buccal cell FXN levels below quantifiable levels at baseline, day 14 and day 28, and two participants had buccal FXN levels below quantifiable levels at day 14 and day 28. Key Phase 2 Pharmacokinetic and Safety Data for 25 mg and 50 mg Cohorts of Nomlabofusp: Quick absorption after subcutaneous administration of nomlabofusp with dose proportional increases in exposure were observed with increasing doses. Generally well tolerated with no serious adverse events reported. No severe adverse events in the 50 mg cohort. One severe adverse event for an allergic reaction to the study drug was reported in the 25 mg cohort and was resolved with standard treatment. 18 of the 19 participants dosed with nomlabofusp completed the trial, with one participant in the 25 mg cohort withdrawing due to the aforementioned allergic reaction that resolved with standard treatment. Most common adverse events were mild and moderate injection site reactions. Updates on the Nomlabofusp Regulatory Pathway in FA: FDA acknowledgment that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. Ongoing discussions with the FDA on evidence needed to support an accelerated approval application, including supplementary nonclinical pharmacology investigations, FXN, supportive PD and clinical outcomes information from the OLE study, and additional clinical safety data. Initiation of a confirmatory study planned prior to BLA submission. Potential BLA submission targeted for 2H 2025.

07:11 EST Precision gets initial $7.5M from TG Therapeutics for azer-cel development - Precision BioSciences (DTIL) received an upfront cash payment and equity investment from TG Therapeutics (TGTX) for an exclusive license to develop Azercabtagene Zapreleucel or azer-cel for autoimmune diseases, and other indications outside of cancer. This is the first in a series of payments, with Precision to receive a total of $17.5M in upfront and potential near-term payments as part of the consideration for this license. In exchange for global rights to azer-cel for autoimmune diseases and indications outside of cancer, Precision has received an upfront payment totaling $7.5N, consisting of cash and the purchase of 2,920,816 shares of Precision common stock by TG Therapeutics at a price of 77c per share, a 100% premium to the 30-day volume-weighted average price prior to purchase. Precision will also receive an additional $2.5 M within 11 months, as an equity investment in Precision's common stock at 100% premium to the then 30-day VWAP prior to purchase. Upon the achievement of certain near-term clinical milestones, Precision will also receive an additional $7.5 million payment. Precision is eligible to receive up to $288M in milestone payments in addition to high-single-digit to low-double-digit royalties on net sales. Precision expects that these recent payments from its azer-cel transactions, along with existing cash and cash equivalents, expected operational receipts, continued fiscal and operating discipline, and availability of Precision's at-the-market ATM facility will extend Precision's cash runway into the first half of 2026, through phase 1 clinical readouts for its wholly owned programs

07:10 EST Beamr Imaging, Nvidia team up to accelerate adoption of AV1 - Beamr Imaging (BMR) announced that it will present its joint research relating to automated video modernization with NVIDIA Corporation (NVDA) at the ACM Mile-High-Video 2024 conference, being held in Denver, Colorado from February 11-14, 2024. Beamr CTO, Tamar Shoham, who will present the research at the conference, explained: "Until today, adopting the upgraded video standard was a complex transition for two reasons - one, the new standard requires significantly more compute power and therefore comes at a very high cost; and two, the new standard requires a steep learning curve as it is difficult to figure out how much added compression can be applied without sacrificing video quality, which results in a lot of uncertainty during the process".

07:09 EST Genasys awarded infrastructure project to engineer, build EWS in Puerto Rico - Genasys announced that it has been selected to engineer, procure and build an Emergency Warning System, EWS, for the hundreds of thousands of residents and visitors living downstream of 37 dams in Puerto Rico. The competitive award made by the Puerto Rico Electric Power Authority, PREPA, is fully funded by $94.3 million from the U.S. Federal Emergency Management Agency, FEMA. Genasys expects to recognize $60 million to $70 million in revenue over the term of the project. The Genasys ProtectTM platform enables early detection and communication of potential flood threats via sensors, predictive analytics, and the Genasys Protect software and ACOUSTICS offerings. Genasys' proposal was unanimously selected by all parties, topping all criteria categories. The proposal incorporates the Genasys Protect platform, which includes proprietary software and hardware solutions, with sensors and communication equipment. Genasys CEO Richard Danforth said, "Although the competitive RFP process for this award started just last October, Genasys has been working with FEMA, PREPA, and the government of Puerto Rico since the devastating hurricane Maria in 2017. Today's announcement represents the most comprehensive implementation of Genasys Protect for Critical Infrastructure Protection to date and is a testament to the value of Genasys' Protective Communications solutions."

07:07 EST Universal Stainless announces base increase of 7%-12% on premium products - Universal Stainless & Alloy Products announced a base price increase of 7 - 12% on premium products. The increase goes into effect immediately. Current material and energy surcharges will remain in effect. Brian Kane, Vice President Sales & Marketing, commented "The price adjustment is necessary to continue investments needed to support the demand from specialty steel markets."

07:07 EST Plug Power delivers several portable liquid hydrogen refuelers to customers - Plug Power delivered several first-of-its-kind liquid hydrogen portable refuelers to transit agencies and trucking fleet customers. Plug's HL-450D-P is a complete hydrogen refueling station on a portable platform that can be quickly and easily deployed to support fleet vehicle hydrogen refueling at either 350 bar or 700 bar, with minimal site preparation and needing only a single electrical connection. "Our portable refueler product is a prime example of Plug's cutting-edge innovation driving cost-effective adoption of hydrogen in hard-to-abate sectors like transportation," said Andy Marsh, Plug CEO. "With minimal upfront costs, mass transit authorities, logistics companies, and retailers can now quickly pop up low-carbon hydrogen refueling infrastructure to support their fleets." Plug's portable refueler is ideal for initial fleet deployments that require a high performance fueling solution at small scale, and delays the need for construction of a permanent fueling station.

07:06 EST Akoustis receives Wi-Fi 7 design win from Tier-1 U.S. based carrier - Akoustis Technologies announced that two of its patented XBAW filters are being integrated into a Wi-Fi 7 router platform with a leading US-based carrier, catering to more than 32 million residential customers. Jeff Shealy, founder and CEO of Akoustis, commented, "Receiving this design win signifies another completed milestone and reflects our prominent standing in the Wi-Fi market." Mr. Shealy continued, "The incorporation of Akoustis' Wi-Fi 7 coexistence filters into the carrier's 4x4 MIMO Wi-FI AP router platform demonstrates our advancements in technology and delivering superior performance for small carrier routers."

07:04 EST Blue Water Industries to sell certain aggregates operations to Martin Marietta - Blue Water Industries has entered into a definitive agreement with Martin Marietta Materials, under which Martin Marietta will acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from Blue Water Industries' affiliate for $2.05B in cash. Blue Water Industries is a privately-held, pure-play construction aggregates producer in the United States. Its footprint spans seven states, including Florida, Tennessee, North Carolina, South Carolina, Alabama, Mississippi, and Virginia, and serves some of the fastest growing regions of the Southeast United States. The BWI Southeast transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions. Blue Water Industries will continue to operate its aggregates operations in North Carolina and central Florida, as well as its marine terminal business. Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Blue Water Industries. The Greystone Group is serving as financial advisor to Blue Water Industries.

07:02 EST SU Group wins major customer security project in Hong Kong - SU Group Holdings announced it has won a major customer security project to provide security engineering services for a property complex in Hong Kong. Under the agreement, SU Group will design, supply and implement a comprehensive, integrated Extra Low Voltage security solution. The tailored solution will include integration of a high-definition CCTV system, with both state-of-the-art detection and image processing, a communications system, high-speed WiFi, secure mailbox access, and a video-enabled door security system. SU Group will also provision a CABD system, which will serve as an amplifier to prevent weak signals at the property.

06:58 EST Martin Marietta acquires aggregates operations, completes cement divestiture - Martin Marietta entered into a definitive agreement to acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries for $2.05B in cash. Additionally, on February 9, the company completed its divesture of its South Texas cement and related concrete operations to CRH Americas Materials, a subsidiary of CRH, for $2.1B in cash. The BWI Southeast transaction will be financed with balance sheet cash and is expected to close later this year, subject to regulatory approvals and other customary closing conditions.

06:46 EST Lazard reports preliminary AUM $243.8B as of January 31 - Lazard reported that its preliminary assets under management as of January 31 totaled approximately $243.8B. The month's AUM included foreign exchange depreciation of $2.3B, net outflows $2.1B and market appreciation of $1.6B.

06:32 EST Babcock & Wilcox Canada awarded $13M emission reduction contract by refinery - Babcock & Wilcox subsidiary Babcock & Wilcox Canada has been awarded a contract for more than $13M to supply equipment and design and engineering services to help a petroleum refinery in North America comply with environmental regulations. B&W will supply 18 high-efficiency, low-NOx burners for the reduction of nitrogen oxides emissions for three units at the plant. B&W will also design a flue gas recirculation system, provide performance engineering services, supply fans, and other equipment for one of the units. Work has begun on the equipment supply, which is scheduled for delivery in Q4.

06:09 EST Diamondback Energy sees 'substantial' accretion from Endeavor deal - Strategic and Financial Benefits: Combined pro forma scale of approximately 838,000 net acres and 816 MBOE/d of net production. Best in-class inventory depth and quality with approximately 6,100 pro forma locations with break evens at less than$40 WTI. Annual synergies of $550 million representing over $3.0 billion in NPV10 over the next decade. Capital and operating cost synergies: approximately $325 million. Capital allocation and land synergies: approximately $150 million. Financial and corporate cost synergies: approximately $75 million. Substantial near and long-term financial accretion with ~10% free cash flow per share accretion expected in 2025. Stock-weighted transaction solidifies investment grade balance sheet. Advances leading ESG profile. "This combination offers significant, tangible synergies that will accrue to the pro forma stockholder base," stated CEO Travis Stice. "Diamondback has proven itself to be a premier low-cost operator in the Permian Basin over the last twelve years, and this combination allows us to bring this cost structure to a larger asset and allocate capital to a stronger pro forma inventory position. We expect both teams will learn from each other and implement best practices to improve combined capital efficiency for years to come."

06:06 EST Diamondback Energy sees FY25 capital budget $4.1B-$4.4B - Diamondback expects operational synergies to be realized in 2025 by the combined company. Therefore, the company is providing a preliminary look at its pro forma 2025 combined company capital and operating plan assuming Diamondback's cost structure and current estimated well costs. The 2025 plan is preliminary and subject to changes, including as result of changes in oil and gas prices, the macro environment and well costs. On a pro forma basis in 2025, Diamondback expects to generate oil production of 470 - 480 MBO/d (800 - 825 MBOE/d) with a capital budget of approximately $4.1B-$4.4B. This operating plan implies significant pro forma cash flow and free cash flow per share accretion.

06:05 EST Diamondback Energy sees Q4 production 273.1 MBO/d (462.6 MBOE/d) - Diamondback is releasing selected operating information for the fourth quarter of 2023 and providing initial production and capital guidance for 2024. Average fourth quarter 2023 production of 273.1 MBO/d (462.6 MBOE/d). Fourth quarter 2023 cash capital expenditures of $649 million. On a stand-alone basis in 2024 Diamondback expects to generate oil production of 270 - 275 MBO/d (458 - 466 MBOE/d) with a total capital budget of approximately $2.3 - $2.55 billion. Beginning in the first quarter of 2024, Diamondback will reduce its return of capital commitment to at least 50% of free cash flow to stockholders from at least 75% of free cash flow previously. "Diamondback today released fourth quarter production that exceeded expectations and announced a 2024 capital and operating plan that prioritizes capital efficiency and free cash flow generation over growth," stated Travis Stice. "The decision to reduce our return of capital to stockholders reflects our Board's desire to increase financial flexibility and pay down debt added through this combination. Our near-term objective is to reduce pro forma net debt below $10 billion very quickly, ensuring balance sheet strength and best-in-class credit quality. Return of capital to stockholders will always remain a core tenet of our value proposition and capital allocation philosophy at Diamondback."

06:03 EST Diamondback Energy board to approve 7% dividend increase - Diamondback announced that the company's Board of Directors will approve a 7% increase to its base dividend to $3.60 per share annually, or 90c per share quarterly, effective for the fourth quarter of 2023.

06:00 EST Diamondback Energy, Endeavor Energy Resources to merge in $26B deal

05:49 EST Meta won't recommend content about politics across Instagram, Threads - Meta announced Friday: "We want Instagram and Threads to be a great experience for everyone. If you decide to follow accounts that post political content, we don't want to get between you and their posts, but we also don't want to proactively recommend political content from accounts you don't follow. So we're extending our existing approach to how we treat political content - we won't proactively recommend content about politics on recommendation surfaces across Instagram and Threads. If you still want these posts recommended to you, you will have a control to see them. These recommendations updates apply to public accounts and in places where we recommend content such as Explore, Reels, In-Feed Recommendations and Suggested Users - it doesn't change how we show people content from accounts they choose to follow. If political content - potentially related to things like laws, elections, or social topics - is posted by an account that is not eligible to be recommended, that account's content can still reach their followers in Feed and Stories... We're always working to improve our recommendation systems and give people control so we can connect people with the most relevant posts to them. We'll roll out these changes slowly over time to get this right." Reference Link